Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Feb;55(1):66-9.
doi: 10.1503/cjs.036011.

CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis

Affiliations
Comment

CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis

Steve Latosinsky et al. Can J Surg. 2012 Feb.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

Cited by

References

    1. Evidence-Based Medicine Working Group. Evidence-based medicine. JAMA. 1992;268:2420–5. - PubMed
    1. Lin PP, Allison D, Wainstock J, et al. Impact of axillary lymph node dissection on therapy of breast cancer patients. J Clin Oncol. 1993;11:1536–44. - PubMed
    1. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75. - PubMed
    1. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. - PubMed
    1. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph node resection compared with conventional axillary-lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. - PMC - PubMed

Publication types